COYA Relative Valuation
COYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COYA is overvalued; if below, it's undervalued.
Historical Valuation
Coya Therapeutics Inc (COYA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.14. The fair price of Coya Therapeutics Inc (COYA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.99
Fair
-4.01
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Coya Therapeutics Inc. (COYA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.73. The thresholds are as follows: Strongly Undervalued below -7.06, Undervalued between -7.06 and -4.39, Fairly Valued between 0.93 and -4.39, Overvalued between 0.93 and 3.60, and Strongly Overvalued above 3.60. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-3.55
EV/EBIT
Coya Therapeutics Inc. (COYA) has a current EV/EBIT of -3.55. The 5-year average EV/EBIT is -3.86. The thresholds are as follows: Strongly Undervalued below -8.01, Undervalued between -8.01 and -5.93, Fairly Valued between -1.78 and -5.93, Overvalued between -1.78 and 0.29, and Strongly Overvalued above 0.29. The current Forward EV/EBIT of -3.55 falls within the Historic Trend Line -Fairly Valued range.
54.59
PS
Coya Therapeutics Inc. (COYA) has a current PS of 54.59. The 5-year average PS is 18.80. The thresholds are as follows: Strongly Undervalued below -12.04, Undervalued between -12.04 and 3.38, Fairly Valued between 34.22 and 3.38, Overvalued between 34.22 and 49.64, and Strongly Overvalued above 49.64. The current Forward PS of 54.59 falls within the Strongly Overvalued range.
0.00
P/OCF
Coya Therapeutics Inc. (COYA) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.62. The thresholds are as follows: Strongly Undervalued below -12.66, Undervalued between -12.66 and -8.64, Fairly Valued between -0.60 and -8.64, Overvalued between -0.60 and 3.42, and Strongly Overvalued above 3.42. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Coya Therapeutics Inc. (COYA) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.07. The thresholds are as follows: Strongly Undervalued below -6.82, Undervalued between -6.82 and -4.44, Fairly Valued between 0.31 and -4.44, Overvalued between 0.31 and 2.69, and Strongly Overvalued above 2.69. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Coya Therapeutics Inc (COYA) has a current Price-to-Book (P/B) ratio of 3.77. Compared to its 3-year average P/B ratio of 3.01 , the current P/B ratio is approximately 25.22% higher. Relative to its 5-year average P/B ratio of 3.01, the current P/B ratio is about 25.22% higher. Coya Therapeutics Inc (COYA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -13.94%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -13.94% , the current FCF yield is about -100.00% lower.
3.68
P/B
Median3y
3.01
Median5y
3.01
-9.44
FCF Yield
Median3y
-13.94
Median5y
-13.94
Competitors Valuation Multiple
The average P/S ratio for COYA's competitors is 0.00, providing a benchmark for relative valuation. Coya Therapeutics Inc Corp (COYA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of COYA increased by 4.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 3.56M.
The secondary factor is the Margin Expansion, contributed -82.38%to the performance.
Overall, the performance of COYA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Coya Therapeutics Inc (COYA) currently overvalued or undervalued?
What is Coya Therapeutics Inc (COYA) fair value?
How does COYA's valuation metrics compare to the industry average?
What is the current P/B ratio for Coya Therapeutics Inc (COYA) as of Dec 05 2025?
What is the current FCF Yield for Coya Therapeutics Inc (COYA) as of Dec 05 2025?
What is the current Forward P/E ratio for Coya Therapeutics Inc (COYA) as of Dec 05 2025?